Equities

Arecor Therapeutics PLC

AREC:LSE

Arecor Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)131.00
  • Today's Change0.00 / 0.00%
  • Shares traded5.78k
  • 1 Year change-48.63%
  • Beta--
Data delayed at least 20 minutes, as of May 17 2024 15:44 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Income statement information is not available for Arecor Therapeutics PLC.
Gross margin--
Net profit margin-278.81%
Operating margin-306.51%
Return on assets-50.32%
Return on equity-67.81%
Return on investment-66.40%
More ▼

Cash flow in GBPView more

In 2022, cash reserves at Arecor Therapeutics PLC fell by 13.55m. Cash Flow from Financing totalled 5.16m or 214.73% of revenues. In addition the company used 10.78m for operations while cash used for investing totalled 7.99m.
Cash flow per share-0.2924
Price/Cash flow per share--
Book value per share0.4314
Tangible book value per share0.3237
More ▼

Balance sheet in GBPView more

Arecor Therapeutics PLC has little financial risk as the capital structure does not rely on leverage.
Current ratio2.52
Quick ratio2.28
Total debt/total equity0.0126
Total debt/total capital0.0125
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.